Finerenone: Difference between revisions
CSV import |
No edit summary |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
<gallery> | <gallery> | ||
File:Finerenone.svg|Finerenone | File:Finerenone.svg|Finerenone | ||
</gallery> | </gallery> | ||
Latest revision as of 21:53, 16 March 2025
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that is used in the treatment of chronic kidney disease (CKD) and type 2 diabetes. It is developed by Bayer, a German multinational pharmaceutical company.
Mechanism of Action[edit]
Finerenone works by blocking the mineralocorticoid receptor, which is a nuclear receptor that regulates the balance of salt and water in the body. This receptor is activated by hormones such as aldosterone and cortisol. By blocking this receptor, finerenone helps to reduce the risk of cardiovascular disease in patients with CKD and type 2 diabetes.
Clinical Trials[edit]
Finerenone has been studied in several clinical trials. The FIDELIO-DKD trial showed that finerenone reduced the risk of kidney failure and cardiovascular events in patients with CKD and type 2 diabetes. The FIGARO-DKD trial is currently ongoing and is expected to provide further evidence on the efficacy and safety of finerenone.
Side Effects[edit]
The most common side effects of finerenone include hyperkalemia (high potassium levels in the blood), hypotension (low blood pressure), and hyponatremia (low sodium levels in the blood). Patients should be monitored for these side effects during treatment with finerenone.
Contraindications[edit]
Finerenone is contraindicated in patients with hyperkalemia or anuria (absence of urine production). It should also be used with caution in patients with severe renal impairment or adrenal insufficiency.
